Physician profile
Dima Ezzedine
NPI 1922480391
$6,777.13
in general payments reported to CMS, 2019-2025
22 companies · $304 in 2025
The $304 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $282 · 2020: $45.04 · 2021: $1,394 · 2022: $2,641 · 2023: $1,454 · 2024: $657 · 2025: $304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,235 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,235.04 |
| Education | $179.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,742.79 | 2019-2025 | Upsylon, Advantage System |
| Axonics, INC. | $1,394.88 | 2022-2024 | Axonics, Bulkamid |
| Intuitive Surgical, INC. | $1,229.26 | 2021-2023 | Da Vinci Surgical System |
| Medtronic, INC. | $532.35 | 2021-2023 | Interstim |
| Astellas Pharma US INC | $462.25 | 2023-2024 | Veozah, Myrbetriq |
| Dentsply Ih Ab | $458.12 | 2023-2024 | Lofric, Lofric |
| Allergan, INC. | $231.30 | 2019-2021 | |
| Medtronic USA, INC. | $124.44 | 2019 | |
| Sumitomo Pharma America, INC. | $114.00 | 2023-2025 | Gemtesa |
| Abbvie INC. | $79.01 | 2023-2025 | |
| Coloplast Corp | $59.93 | 2020-2025 | |
| Pfizer INC. | $55.86 | 2023-2024 | |
| Dendreon Pharmaceuticals LLC | $48.73 | 2025 | Provenge |
| 180 Medical, INC. | $47.97 | 2023-2025 | Gentlecath |
| Urovant Sciences INC | $34.98 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| C. R. Bard, INC. & Subsidiaries | $31.56 | 2024 | Bard Urinary Drainage Bag |
| Accord Healthcare, INC. | $24.58 | 2024 | |
| Endo Pharmaceuticals INC. | $23.37 | 2022 | |
| Rochester Medical Corporation | $23.17 | 2022 | |
| Mission Pharmacal Company | $21.84 | 2023 | Uribel |
| Laborie Medical Technologies Corp. | $18.50 | 2023 | |
| Valencia Technologies Corporation | $18.24 | 2025 | Ecoin Device Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dima Ezzedine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.